Related Experiment Video
Updated: May 20, 2026
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Addiction to c-MYC in multiple myeloma
Toril Holien1, Thea Kristin Våtsveen, Hanne Hella
1KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. toril.holien@ntnu.no
Blood
|July 19, 2012
Summary
Inhibition of c-MYC activity using 10058-F4 effectively induces cell death in multiple myeloma. This study shows c-MYC is a promising therapeutic target for treating this blood cancer.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- c-MYC activation is crucial for the malignant phenotype in multiple myeloma.
- Previous studies using short hairpin RNA showed MYC inhibition induces cell death in myeloma cell lines.
- Myeloma cell lines may not accurately represent primary patient cells due to advanced disease staging.
Purpose of the Study:
- To investigate the efficacy of a small molecule inhibitor of MYC-MAX heterodimerization (10058-F4) in multiple myeloma.
- To determine if c-MYC inhibition induces cell death in both myeloma cell lines and primary patient cells.
- To assess the impact of c-MYC inhibition in a more complex in vitro model involving patient-derived bone marrow stromal cells.
Main Methods:
- Treatment of multiple myeloma cell lines and primary myeloma cells with the selective MYC-MAX inhibitor 10058-F4.
- Evaluation of apoptosis induction in response to c-MYC inhibition.
- Coculture experiments using myeloma cell lines with bone marrow stromal cells from multiple myeloma patients.
Main Results:
- The small molecule inhibitor 10058-F4 efficiently induced myeloma cell death.
- Inhibition of c-MYC activity led to apoptosis in both myeloma cell lines and primary myeloma cells.
- 10058-F4 effectively induced apoptosis even in cocultures with patient-derived bone marrow stromal cells.
Conclusions:
- Multiple myeloma cells are dependent on c-MYC activity for survival.
- Targeting c-MYC with inhibitors like 10058-F4 is a promising therapeutic strategy for multiple myeloma.
- The findings support c-MYC as a viable therapeutic target in multiple myeloma treatment.
More Related Videos
Related Concept Videos
01:06Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...